---
id: 240
title: Escherichia coli
category: organisms
subcategory: gram_negative_rods
tags: [E-coli, ESBL, UTI, bacteremia, STEC, O157H7]
difficulty: medium
---

## Question

What are key clinical syndromes and treatment considerations for *E. coli*? Use **"UTI (Most Common), Bacteremia, ESBL Risk, STEC (Do NOT Treat)"** framework.

## Answer

### **Key Clinical Syndromes:**

**Urinary Tract Infections:**
- **Most common cause** of community-acquired UTI (75-95%)
- **Most common cause** of pyelonephritis
- **Cystitis, pyelonephritis, prostatitis**

**Bacteremia/Sepsis:**
- **Most common Gram-negative bacteremia** (often GU or GI source)
- **Mortality 15-30%** (if septic shock)

**Intra-Abdominal Infections:**
- **Polymicrobial** (with anaerobes)
- **Diverticulitis, appendicitis, cholangitis, SBP**

**Diarrheal Illnesses:**
- **STEC (O157:H7):** Shiga toxin → HUS
- **ETEC:** Traveler's diarrhea (watery)
- **EPEC, EAEC:** Pediatric diarrhea

**Neonatal Meningitis:**
- **K1 capsule** (evades immunity)

### **Antimicrobial Resistance:**

**ESBL (Extended-Spectrum Beta-Lactamase):**
- **Resistance to:** Penicillins, cephalosporins (including 3rd-generation)
- **Treat with:** Carbapenems (ertapenem, meropenem)
- **Risk factors:** Recent antibiotics, healthcare exposure, travel to high-prevalence areas (South Asia)

**Carbapenem-Resistant *E. coli* (CRE):**
- **Rare but emerging**
- **Often colistin-resistant** as well
- **Treat with:** Ceftazidime-avibactam, meropenem-vaborbactam, or newer agents

**AmpC Beta-Lactamase:**
- **Intrinsic resistance** to ampicillin, 1st-generation cephalosporins
- **Cephalosporinase** (can be induced)

### **Treatment by Syndrome:**

**Uncomplicated Cystitis:**
- **Nitrofurantoin 100mg BID × 5 days** (first-line)
- **TMP-SMX DS BID × 3 days** (if local resistance <20%)
- **Fosfomycin 3g × 1** (single dose)

**Pyelonephritis (Uncomplicated):**
- **Ciprofloxacin 500mg BID × 7 days** OR **levofloxacin 750mg daily × 5 days**
- **Ceftriaxone 1-2g IV × 1** → oral step-down

**Complicated UTI/Pyelonephritis:**
- **Ceftriaxone 1-2g IV daily** (if no ESBL risk)
- **If ESBL:** Ertapenem 1g IV daily OR meropenem 1g IV q8h

**Bacteremia/Sepsis:**
- **Ceftriaxone 2g IV daily** (if susceptible, no ESBL)
- **If ESBL:** Meropenem 1g IV q8h OR ertapenem 1g IV daily
- **Duration:** 7-14 days (longer if complicated, slow response)

**Intra-Abdominal Infections:**
- **Pip-tazo 3.375-4.5g IV q6-8h** (covers *E. coli* + anaerobes)
- **Ceftriaxone 2g IV daily + metronidazole 500mg IV q8h**
- **If ESBL:** Meropenem 1g IV q8h

**STEC (O157:H7):**
- **DO NOT give antibiotics** (increases HUS risk)
- **Supportive care only**

### **Virulence Factors:**

**Uropathogenic *E. coli* (UPEC):**
- **P-fimbriae** (adhere to uroepithelium)
- **Type 1 fimbriae**

**STEC (O157:H7):**
- **Shiga toxin** (Stx1, Stx2) → endothelial damage → HUS

**Neonatal Meningitis:**
- **K1 capsule** (antiphagocytic, crosses BBB)

### **Special Considerations:**

**ESBL Screening:**
- **If risk factors:** Recent antibiotics, healthcare exposure, previous ESBL
- **Send urine/blood culture** for ESBL testing (molecular or phenotypic)

**Empiric Coverage:**
- **Uncomplicated community-acquired:** Standard agents (ceftriaxone, fluoroquinolones)
- **Healthcare-associated or ESBL risk:** Carbapenem (ertapenem, meropenem)

## Key Points

### **Most Common UTI Pathogen:**
- **75-95%** of community-acquired UTI

### **ESBL Risk:**
- **Recent antibiotics, healthcare exposure, travel (South Asia)**
- **Treat with carbapenem** (ertapenem, meropenem)

### **STEC: Do NOT Treat:**
- **Antibiotics increase HUS risk**
- **Supportive care only**

### **Bacteremia Treatment:**
- **Ceftriaxone** (if susceptible)
- **Carbapenem** (if ESBL)

### **Clinical Pearls:**
- **Most common UTI pathogen** (75-95%)
- **ESBL risk:** Recent antibiotics, healthcare exposure → carbapenem
- **STEC (O157:H7):** Do NOT give antibiotics (↑HUS risk)
- **Bacteremia:** Ceftriaxone (if susceptible) OR carbapenem (if ESBL)
- **Intra-abdominal:** Pip-tazo OR ceftriaxone + metronidazole

## Sources

- [IDSA: UTI Guidelines 2024]
- [CID: ESBL *E. coli* 2024]

## Media

N/A
